World Journal of Gastroenterology

World J Gastroenterol 2022 June 7; 28(21): 2251-2402

Published by Baishideng Publishing Group Inc
REVIEW

2251 Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment
Stella L, Santopaoaol F, Gasharrini A, Pompili M, Ponziani FR

MINIREVIEWS

2282 Updates in therapeutic drug monitoring in inflammatory bowel disease
Lodhia N, Rao S

2291 Serological biomarkers for management of primary sclerosing cholangitis
Tornai D, Ven PL, Lakatos PL, Papp M

ORIGINAL ARTICLE

Basic Study

2302 Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma

Case Control Study

2320 Intermittent hypoxia is involved in gut microbial dysbiosis in type 2 diabetes mellitus and obstructive sleep apnea-hypopnea syndrome

Retrospective Study

2334 Serotonin type 3 receptor subunit gene polymorphisms associated with psychosomatic symptoms in irritable bowel syndrome: A multicenter retrospective study

2350 Differentiating malignant and benign focal liver lesions in children using CEUS LI-RADS combined with serum alpha-fetoprotein
Jiang ZP, Zeng KY, Huang JY, Yang J, Yang R, Li JW, Qiu TT, Luo Y, Lu Q

Observational Study

2361 Socioeconomics and attributable etiology of primary liver cancer, 1990-2019
Xing QQ, Li JM, Dong X, Zeng DY, Chen ZJ, Lin XY, Pan JS
SYSTEMATIC REVIEWS

2383 Endoscopic ultrasound-guided injectable therapy for pancreatic cancer: A systematic review
Kaur J, Jaruvongvanich V, Chandrasekhara V

LETTER TO THE EDITOR

2396 Peripancreatic paraganglioma: Lesson from a round table
### ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Somashekar G Krishna, MD, MPH, AGAF, FASGE, FACC, Professor of Medicine, Director of Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Room 226, Columbus, OH 43210, United States. somashekar.krishna@osumc.edu

### AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

### INDEXING/ABSTRACTING

The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Report® cites the 2020 impact factor (IF) for WJG as 5.742; Journal Citation Indicator: 0.79; IF without journal self cites: 5.590; 5-year IF: 5.044; Ranking: 28 among 92 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2020 is 6.9 and Scopus CiteScore rank 2020: Gastroenterology is 19/136.

### RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Ze-Mao Gong.

---

**NAME OF JOURNAL**  
*World Journal of Gastroenterology*

**ISSN**  
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**  
October 1, 1995

**FREQUENCY**  
Weekly

**EDITORS-IN-CHIEF**  
Andrzej S Tarnawski

**EDITORIAL BOARD MEMBERS**  
http://www.wjgnet.com/1007-9327/editorialboard.htm

**PUBLICATION DATE**  
June 7, 2022

**COPYRIGHT**  
© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**  
https://www.wjgnet.com/bpg/gerinfo/204

**GUIDELINES FOR ETHICS DOCUMENTS**  
https://www.wjgnet.com/bpg/gerinfo/287

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**  
https://www.wjgnet.com/bpg/gerinfo/240

**PUBLICATION ETHICS**  
https://www.wjgnet.com/bpg/gerinfo/288

**PUBLICATION MISCONDUCT**  
https://www.wjgnet.com/bpg/gerinfo/208

**ARTICLE PROCESSING CHARGE**  
https://www.wjgnet.com/bpg/gerinfo/242

**STEPS FOR SUBMITTING MANUSCRIPTS**  
https://www.wjgnet.com/bpg/gerinfo/239

**ONLINE SUBMISSION**  
https://www.f6publishing.com

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
E-mail: bpgoffice@wjgnet.com  
https://www.wjgnet.com
Case Control Study

Intermittent hypoxia is involved in gut microbial dysbiosis in type 2 diabetes mellitus and obstructive sleep apnea-hypopnea syndrome

Sha-Sha Tang, Cheng-Hong Liang, Ya-Lei Liu, Wei Wei, Xin-Ru Deng, Xiao-Yang Shi, Li-Min Wang, Li-Jun Zhang, Hui-Juan Yuan

Sha-Sha Tang, Cheng-Hong Liang, Ya-Lei Liu, Wei Wei, Xin-Ru Deng, Xiao-Yang Shi, Li-Min Wang, Li-Jun Zhang, Hui-Juan Yuan, Department of Endocrinology, Henan Provincial Key Medicine Laboratory of Intestinal Microecology and Diabetes, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou 450003, Henan Province, China

Corresponding author: Hui-Juan Yuan, PhD, Chief Doctor, Department of Endocrinology, Henan Provincial Key Medicine Laboratory of Intestinal Microecology and Diabetes, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, No. 7 Weiwu Road, Zhengzhou 450003, Henan Province, China. hjyuan@zzu.edu.cn

Abstract

BACKGROUND
Obstructive sleep apnea (OSA)-hypopnea syndrome (OSAHS) has been recognized as a comorbidity of type 2 diabetes mellitus (T2DM); more than half of T2DM patients suffer from OSAHS. Intermittent hypoxia (IH) plays an important role in metabolic diseases, such as obesity and OSAHS, through various mechanisms, including altering the gut microecological composition and function. Therefore, it is important to study the role of gut microbiota in T2DM patients with OSAHS, which has a high incidence and is prone to several complications.

AIM
To assess whether IH is involved in altering the fecal microbiome in T2DM patients with OSAHS.

METHODS
Seventy-eight participants were enrolled from Henan Province People’s Hospital and divided into healthy control (HC, n = 26), T2DM (n = 25), and T2DM + OSA (n = 27) groups based on their conditions. The fecal bacterial DNA of the research participants was extracted and subjected to 16S ribosomal RNA sequencing. The clinical indices, such as insulin resistance index, homocysteine (HCY) concentration, and the concentrations of inflammatory factors in the peripheral blood, were assessed and recorded.

RESULTS
Group T2DM + OSA had the highest apnea-hypopnea index (AHI) (2.3 vs 3.7 vs 13.7), oxygen desaturation index (0.65 vs 2.2 vs 9.1), HCY concentration (9.6 vs 10.5 vs 15.0), and the concentration of inflammatory factors in the peripheral blood (vs 13.7), oxygen desaturation index (0.65 vs 2.2 vs 9.1), HCY concentration (9.6 vs 10.5 vs 15.0), and the concentration of inflammatory factors in the peripheral blood (vs 13.7), oxygen desaturation index (0.65 vs 2.2 vs 9.1), HCY concentration (9.6 vs 10.5 vs 15.0), and the concentration of inflammatory factors in the peripheral blood (vs 13.7), oxygen desaturation index (0.65 vs 2.2 vs 9.1), HCY concentration (9.6 vs 10.5 vs 15.0), and the concentration of inflammatory factors in the peripheral blood (vs 13.7), oxygen desaturation index (0.65 vs 2.2 vs 9.1), HCY concentration (9.6 vs 10.5 vs 15.0), and the concentration of inflammatory factors in the peripheral blood (vs 13.7), oxygen desaturation index (0.65 vs 2.2 vs 9.1), HCY concentration (9.6 vs 10.5 vs 15.0), and the concentration of inflammatory factors in the peripheral blood.
μmol/L vs 10.3 μmol/L vs 13.81 μmol/L) and C-reactive protein (CRP) concentrations (0.3 mg/L vs 1.43 mg/L vs 2.11 mg/L), and lowest mean oxygen saturation (97.05% vs 96.6% vs 94.7%) among the three groups. Twelve and fifteen key differences in amplicon sequence variants were identified when comparing group T2DM + OSA with groups T2DM and HC, respectively. We found progressively decreased levels of Faecalibacterium, Eubacterium, and Lachnospiraceae, and an increase in the level of Actinomyces, which strongly correlated with the HCY, CRP, fasting plasma glucose, and hemoglobin A1c concentrations, AHI, mean oxygen saturation, and insulin resistance index in group T2DM + OSA (P < 0.05).

CONCLUSION
For T2DM patients with OSAHS, IH may be involved in selective alterations of the gut microbiota, which may affect the pathophysiological development of T2DM and DM-related complications.

Key Words: Gut microbiota; Obstructive sleep apnea-hypopnea syndrome; Type 2 diabetes mellitus; Intermittent hypoxia; Obstructive sleep apnea

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Clinically, type 2 diabetes mellitus (T2DM) patients have a significantly higher prevalence of obstructive sleep apnea-hypopnea syndrome (OSAHS) than non-T2DM patients and are more prone to diabetes-related complications and metabolic syndrome, including obesity and hypertension. In recent years, the imbalance of gut microbiota has been found to be associated with various metabolic disorders. This study revealed that intermittent hypoxia was associated with changes in the gut microbiota in patients with T2DM complicated by OSAHS. These changes may be involved in the progression of metabolic disorders through increased proinflammatory factors and impaired intestinal barrier function.

URL: https://www.wjgnet.com/1007-9327/full/v28/i21/2320.htm

INTRODUCTION
Obstructive sleep apnea (OSA)-hypopnea syndrome (OSAHS) is characterized by recurrent partial or complete pharyngeal obstruction during sleep[1], resulting in intermittent hypoxia (IH); cyclical adverse changes in heart rate, blood pressure (BP), and sympathetic activity; and disruption of sleep architecture[2]. Epidemiological studies have shown that OSAHS is a globally prevalent chronic sleep disorder, especially in adults with type 2 diabetes mellitus (T2DM), with rates varying from 23% to 87%[3,4]. Moderate to severe OSAHS has been found to be associated with an increase in the incidence of T2DM, and the incidence of OSAHS in patients with T2DM was > 50% higher than that in those without diabetes, independent of traditional risk factors, such as obesity and other confounders. IH, a hallmark of OSAHS, plays an important role not only in the pathogenesis of OSAHS but also in reducing glycemic control and insulin resistance in patients with T2DM and diabetes-related complications[5-7], probably by activating several systematic inflammatory mediators and enhancing the oxidative stress cascade and hypothalamic-pituitary-adrenal function, among others[8].

Commensal bacteria, termed microbiota, cover every surface of our body exposed to the external environment, with 70% of these residing in the gastrointestinal tract[9]. The microbiome is a vast and complex polymicrobial ecosystem that coexists with the human organism and has been identified as playing important roles in the development of host immunological phenotypes. Gut microbiota dysbiosis has been linked to a series of metabolic disorders, such as diabetes and hypertension[10]. In a study of IH mimicking OSAHS, in an Ldlr−/− mice fed a high-fat diet, the imbalance of gut microbiota was found to be associated with adverse cardiovascular events and metabolic disorders[11,12]. Similarly, sleep fragmentation induced by OSAHS alters feeding behavior and promotes obesity and metabolic abnormalities, while the host gut microbiome changes, leading to increased intestinal permeability and chronic inflammation of adipose tissues[11,12]. For T2DM patients with OSAHS, only a few studies have focused on the relationship between severe metabolic disorders caused by IH and gut microbial dysbiosis, independent of conventional risk factors, such as obesity and hypertension. Hence, our study aimed to investigate the gut microbiota changes in T2DM patients with OSAHS.
Clinical indices, such as inflammatory factors and homocysteine (HCY), were compared for the groups as well.

**MATERIALS AND METHODS**

**Participants**

In total, 78 participants, including 25 hospitalized patients with T2DM (Group T2DM), 27 hospitalized patients with T2DM complicated by OSAHS (Group T2DM + OSA), and 26 healthy controls (HC) who were examined with a type IV portable monitor (PM, Sleep Fairy-A7, China) overnight (from 10 p.m. to 7 a.m.), were recruited from July 2019 to July 2020. Most of the sleep recording took place in a quiet and comfortable hospital ward at Henan Provincial People’s Hospital; the remainder was performed by participants sleeping at home after being systematically trained in using the PM. The patient-reported periods before sleep onset and after awakening in the morning were excluded before manual scoring [13]. We collected fasting blood and fecal samples the next morning. General questionnaires were used to collect information on demographic characteristics and health status.

**OSAHS assessment**

Pulse oximetry was used to assess oxyhemoglobin saturation, and respiratory effort was measured with a pneumatic sensor attached to an effort belt. Nasal airflow was recorded using a nasal cannula connected to a pressure transducer. The final data were automatically generated by the software system. The scoring rules were based on the 2007 American Academy of Sleep Medicine manual. The apnea-hypopnea index (AHI) was calculated as the total number of episodes of apnea (continuous cessation of airflow for at least 10 s) and hypopnea (reduction in airflow for ≥ 10 s with oxygen desaturation of ≥ 4%) divided by the total duration of sleep events, and OSAHS was defined as an AHI of 5 events/h.

**Inclusion and exclusion criteria**

The inclusion criteria were as follows: (1) Age of 18-70 years; (2) Treatment-naïve type 2 diabetes based on the 1999 World Health Organization Criteria[14]; (3) 6.5% ≤ glycated hemoglobin A1c (HbA1c) ≤ 11%; (4) No antibiotic use within the 12 wk before enrollment and no probiotics and/or prebiotics; and (5) No glucose-lowering drugs other than insulin during the 12 wk before enrollment in patients with diabetes.

The exclusion criteria were as follows: (1) Body mass index (BMI) of > 28 kg/m²; (2) Diagnoses of chronic respiratory disease, central system sleep apnea syndrome, severe heart failure, BP of ≥ 140/90 mmHg, and severe organic diseases such as cancer, myocardial infarction, and stroke; (3) Diagnoses of other types of diabetes, for example, type 1 diabetes; (4) Diagnoses of inflammatory bowel disease, coagulation disorders, connective tissue diseases, or gastrointestinal surgery, except for appendicitis and hernia surgery; (5) Participation in other programs during the previous 3 mo; (6) Alcoholism (drinking more than five times in 1 wk: > 100 g of spirits, 250 g of rice wine, or 5 bottles of beer); (7) Pregnancy; and (8) Taking drugs that may affect respiratory function, for example, anxiolytics, hypnotics, or mood stabilizers.

**Sample collection**

Biological samples and anthropometric data were obtained without medical treatment. Blood samples were collected after overnight fasting and centrifuged using centrifuge (Multifuge X3R, Thermo Fisher Scientific, United States) at 3000 rpm for 20 min after standing at 24 °C for 30 min to obtain serum. Fresh fecal samples, morning urine, and serum samples were immediately frozen on dry ice after collection and stored at -80 °C until further analysis.

**Clinical indices**

Fasting plasma glucose (FPG) concentrations were measured with the Automatic Biochemical Analyzer (TBA-120 FR, Toshiba, Japan). Fasting insulin concentrations were measured using immunochemiluminometric assays (ADVIA Centaur, Siemens A.G., Germany). Plasma HbA1c concentrations were measured by high-performance liquid chromatography (Bio-Rad D-10, Bio-Rad Laboratories Co., Ltd., Germany). Routine blood tests were performed using the Swelab Alfa Cell analyzer (Boule Diagnostics AB, Sweden). The Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) was calculated using the following formula: FPG*FIN/22.5, where FIN is fasting insulin.

**Inflammatory factors and HCY**

C-reactive protein (CRP) and HCY concentrations were measured with the Automatic Biochemical Analyzer. The determination of the plasma concentrations of the lipopolysaccharide-binding protein (LBP), interleukin (IL)-6, IL-17, and transforming growth factor (TGF)-β1 was performed using human ELISA kits according to the manufacturer’s instructions. The ELISA kits for the assessment of the concentrations of human LBP, tumor necrosis factor (TNF)-α, IL-17, and TGF-β1 were all from Cusabio.
Biotech, Wuhan, China. The kits for high sensitivity IL-6 were purchased from Multi-Science, Hangzhou, China.

16S rRNA gene amplification sequencing
The DNA of the participants was extracted using the E.Z.N.A.® Stool DNA Kit (Omega Bio-tek, Inc., Norcross, GA, Unite States). The isolated DNA was used as the template for polymerase chain reaction (PCR) amplification of the V3-V4 region of 16S rRNA genes. The forward primer (341F) was 5'-CCTACGGGNGGCWGCAG-3', and the reverse primer (805R) was 5'-GACTACHVGGGTATC-TAATCC-3'. PCR was performed with an EasyCycler 96 PCR system (Analytik Jena Corp., AG), and the products from different samples were indexed and mixed at equal ratios for sequencing by Shanghai Mobio Biomedical Technology Co. Ltd. using the Miseq platform (Illumina Inc., San Diego, CA, Unite States) according to the manufacturer’s instructions.

Sequencing data analysis
Amplicon sequence variants (ASVs) were identified with the DADA2 algorithm. The representative sequences for each ASV were annotated using the SILVA reference database (SSU138). The alpha diversity metrics (Shannon–Wiener diversity index and Simpson diversity index) were assessed by using Mothur v1.42.1. The non-parametric Mann–Whitney U test was used to test for significant differences between the two groups. The comparison of multiple groups was performed using a non-parametric Kruskal–Wallis test. Principal coordinates analysis (PCoA) based on Bray–Curtis and unweighted UniFrac distance was conducted using the R program (version 3.6.0, http://www.R-project.org/) to display microbiome space between samples. The key ASVs associated with T2DM and OSA were identified by random forest models, and those significantly associated with BMI selected by MaAsLin2 (https://github.com/biobakery/Maaslin2) were removed. A heatmap plot was drawn to indicate the distributions of the rest of the key ASVs. The linear discriminant analysis effect size (LEfSe) method (lefe 1.1, https://github.com/SegataLab/Lefse) was used to detect taxa with differential abundance. PICRUSt2 v2.4.1 (https://github.com/picrust/picrust2/wiki) was used to predict functional abundance based on 16S rRNA gene sequences.

Statistical analyses
Continuous variables are expressed as means ± SD or medians with interquartile ranges for normal distribution data or non-normal distribution data, respectively. Categorical variables are expressed as percentages. All the statistical analyses, including one-way analysis of variance, Kruskal–Wallis test, Mann-Whitney U test, and least significant difference t-test, were performed using SPSS version 26.0, with a two-sided P value of < 0.05 denoting statistical significance. Significant differences were adjusted by Bonferroni correction. The correlation coefficients for the concentrations of the gut microbiota, inflammatory factors, and HCY were evaluated using Spearman correlation.

RESULTS

Clinical parameters and inflammatory levels among three groups
Applying the strict inclusion and exclusion criteria described above, a total of 78 fecal samples were collected for analysis after PM assessment. We characterized the clinical indices and gut microbiomes of patients in groups HC, T2DM, and T2DM + OSA (Figure 1). There were no significant differences in sex and age among the three groups (P > 0.05). Compared with group T2DM, there were no significant differences in the insulin resistance index (HOMA-IR), BMI, waist-to-hip ratio, neck circumference, FPG, HbA1c, systolic BP, and diastolic BP in group T2DM + OSA; however, they were significantly increased compared with those in group HC (P < 0.05).

The HCY level was the highest in group T2DM + OSA compared with the other two groups. Our PM data revealed that the AHI and oxygen desaturation index (ODI) increased significantly, accompanied by a decrease in the mean oxygen saturation (SpO2); group T2DM + OSA had lower SpO2 than group HC. Further details on the clinical parameters of the participants with diverse severities are shown in Table 1.

The concentration of CRP increased gradually from the HC group to the T2DM group and even more in the T2DM + OSA group. In addition, the levels of TNF-α, IL-17, IL-6, and LBP increased and the levels of TGF-β1 decreased in group T2DM + OSA compared with those in group HC, while the level of TNF-α increased compared with that in group T2DM (P < 0.05) (Figure 2 and Supplementary Table 1).

IH is related to differences in the gut microbiota of T2DM + OSA patients
The resulting rarefaction curves showed that the microbial richness of the sampled guts was near saturation at the applied sequencing depth (Supplementary Figure 1), which was sufficient to identify most of the bacterial community members for each microbiome. The alpha diversity of the gut microbiota expressed by the Shannon estimator, ACE estimator, and Simpson index (Figure 3A-C and

---

**Table 1**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group HC</th>
<th>Group T2DM</th>
<th>Group T2DM + OSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Male</td>
<td>Male</td>
<td>Male</td>
</tr>
<tr>
<td>Age</td>
<td>Median</td>
<td>Median</td>
<td>Median</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td>BMI</td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td>Neck circumference</td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td>FPG</td>
<td>Median</td>
<td>Median</td>
<td>Median</td>
</tr>
<tr>
<td>HbA1c</td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td>Systolic BP</td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td>Diastolic BP</td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
</tbody>
</table>

**SpO2**

<table>
<thead>
<tr>
<th>Group</th>
<th>Median SpO2</th>
</tr>
</thead>
<tbody>
<tr>
<td>HC</td>
<td>98.5%</td>
</tr>
<tr>
<td>T2DM</td>
<td>96.8%</td>
</tr>
<tr>
<td>T2DM + OSA</td>
<td>95.6%</td>
</tr>
</tbody>
</table>

**Supplementary Figure 1**

---

**Figure 1**

---

**Figure 2**

---

**Figure 3A-C**

---
Table 1 Participant characteristics and clinical parameters

<table>
<thead>
<tr>
<th></th>
<th>HC (n = 26)</th>
<th>T2DM (n = 25)</th>
<th>T2DM + OSA (n = 27)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>17/9</td>
<td>17/8</td>
<td>21/6</td>
<td>0.584</td>
</tr>
<tr>
<td>Age, yr</td>
<td>45.58 ± 8.81</td>
<td>45.92 ± 13.89</td>
<td>47.59 ± 5.18</td>
<td>0.728</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>24.63 ± 2.61</td>
<td>25.84 ± 3.45</td>
<td>27.03 ± 2.11</td>
<td>0.009</td>
</tr>
<tr>
<td>WHR, cm</td>
<td>0.85 ± 0.06</td>
<td>0.95 ± 0.07</td>
<td>0.98 ± 0.05</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>NC, cm</td>
<td>32.88 ± 3.70</td>
<td>36.25 ± 4.75</td>
<td>38.37 ± 2.31</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>FPG, mmol/L</td>
<td>5.30 (4.70, 5.43)</td>
<td>6.90 (6.30, 8.05)</td>
<td>8.00 (6.40, 9.25)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.50 (1.09, 2.03)</td>
<td>2.10 (1.02, 3.53)</td>
<td>2.38 (1.37, 3.22)</td>
<td>0.099</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>5.30 (5.10, 5.60)</td>
<td>9.70 (7.30, 10.80)</td>
<td>8.70 (7.70, 9.70)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>SBP, mmHg</td>
<td>117.50 (112.00, 123.25)</td>
<td>130.00 (117.00, 143.00)</td>
<td>131.00 (128.00, 144.00)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>DBP, mmHg</td>
<td>71.96 ± 5.44</td>
<td>81.13 ± 11.33</td>
<td>82.26 ± 8.58</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>HCY, μmol/L</td>
<td>9.60 (8.30, 12.53)</td>
<td>10.30 (8.05, 12.03)</td>
<td>13.81 (10.73, 20.54)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>AHI</td>
<td>2.30 (1.48, 3.05)</td>
<td>3.70 (2.00, 4.15)</td>
<td>13.70 (9.80, 20.10)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Mean SpO₂, %</td>
<td>97.05 (96.50, 97.53)</td>
<td>96.60 (96.05, 96.95)</td>
<td>94.70 (93.80, 95.20)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Lowest SpO₂, %</td>
<td>85.50 (82.00, 90.25)</td>
<td>85.00 (76.00, 87.50)</td>
<td>81.00 (73.00, 84.00)</td>
<td>0.002</td>
</tr>
<tr>
<td>ODI</td>
<td>0.65 (0.40, 1.23)</td>
<td>2.20 (1.10, 5.45)</td>
<td>9.10 (5.90, 15.30)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

P value: Comparison of three groups. Data are presented as the mean ± SD or median with interquartile range. The P value was based on Kruskal–Wallis test or one-way ANOVA. Mann–Whitney U test or least significant difference t-test was used to compare two groups. Significant differences were adjusted by Bonferroni correction. WHR: Waist-hip ratio; NC: Neck circumstance; FPG: Fasting plasma glucose; HOMA-IR: Insulin resistance index; HbA1c: Hemoglobin A1c; SBP: Systolic pressure; DBP: Diastolic pressure; HCY: Homocysteine; AHI: Apnea-hypopnea indices; ODI: Oxygen desaturation index; HC: Healthy control; T2DM: Type 2 diabetes mellitus; OSA: Obstructive sleep apnea.

Supplementary Table 2 showed that there were no significant differences in groups HC, T2DM, and T2DM + OSA (P > 0.05). The overall structures of the gut microbiota in the three groups showed a minimal difference as revealed by the PCoA plot (Figure 3D); however, the difference was not significant (Adonis, P > 0.05).

We further analyzed the taxonomic composition and alterations of the gut microbiome. The composition and abundance of the bacterial community in each sample at the phylum and genus levels are shown in Supplementary Figure 2. At the phylum level, Firmicutes and Proteobacteria were the dominant bacteria in groups HC, T2DM, and T2DM + OSA (Figure 4A). At the genus level, we found no significant differences in the relative abundance of Escherichia–Shigella, which had the highest abundance among the three groups (P > 0.05) (Figure 4B). The relative abundance of the following genera significantly differed among groups: Faecalibacterium (P = 0.0434), Streptococcus (P = 0.0393), Haemophilus (P = 0.0286), Phascolarctobacterium (P = 0.0242), and Oscillibacter (P = 0.0274) (Figure 4C). Among the above genera, the levels of Phascolarctobacterium decreased and the levels of Oscillibacter increased in group T2DM + OSA compared with group T2DM, and the levels of Faecalibacterium significantly decreased in group T2DM + OSA compared with group HC. A gradually decreasing trend of Faecalibacterium abundance from group HC to groups T2DM and T2DM + OSA was observed (Figure 4C). Through LEfSe, we also found a significant decrease in the level of Faecalibacterium in group T2DM + OSA (Figure 4D).

We found 12 ASVs associated with gut microbial dysbiosis in group T2DM + OSA compared with group T2DM, including ASV652 (Streptococcus), ASV450 (Clostridiaceae_Clostridium_sensu_stricto), ASV352 (Faecalibacterium), ASV511 (Roseobaria), ASV307 ([Eubacterium]_hallii_group), ASV1000 ([Eubacterium]_elegans_group), ASV995 (Blautia), ASV584 (Eggerthella), ASV355 (Erysipelotrichaceae_UCG-003), ASV87 (Phascolarctobacterium), ASV1112 (Prevotella), and ASV548 (Oscillibacter). On comparing groups HC and T2DM + OSA, 15 ASVs were different: ASV450 (Clostridiaceae_Clostridium_sensu_stricto), ASV511 (Roseobaria), ASV1000 ([Eubacterium]_elegans_group), ASV266 (Lachnospiraceae_unchlssed), ASV763 (Lachnospiraceae_unchlssed), ASV367 (Faecalibacterium), ASV779 (Actinomycyes), ASV986 (Haemophilus), ASV352 (Faecalibacterium), ASV436 (Faecalibacterium), ASV265 (Streptococcus), ASV355 (Erysipelotrichaceae_UCG-003), ASV68 (Blautia), ASV347 (Saccharimonadales), and ASV1022 (Acinetobacter) (Figure 5A). Therein, the relative abundance of ASV1022 (Acinetobacter), ASV367 (Faecalibacterium), and ASV450 was significantly lower in the OSAH group than in the control group, and the level of ASV511 (Roseobaria) was significantly higher in the OSAH group than in the control group, which had the highest abundance among the three groups. The relative abundance of ASV535 ([Eubacterium]_hallii_group) was significantly lower in the OSAH group than in the control group.

Supplementary Table 2:

<table>
<thead>
<tr>
<th>ASV</th>
<th>Group HC</th>
<th>Group T2DM</th>
<th>Group T2DM + OSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASV450</td>
<td>1.02 (0.64, 1.93)</td>
<td>0.84 (0.53, 1.38)</td>
<td>0.16 (0.03, 0.37)</td>
</tr>
<tr>
<td>ASV511</td>
<td>0.26 (0.10, 0.64)</td>
<td>0.51 (0.28, 0.96)</td>
<td>2.61 (1.40, 4.61)</td>
</tr>
<tr>
<td>ASV307</td>
<td>0.12 (0.05, 0.29)</td>
<td>0.24 (0.13, 0.46)</td>
<td>0.52 (0.30, 0.88)</td>
</tr>
<tr>
<td>ASV995</td>
<td>0.06 (0.02, 0.15)</td>
<td>0.12 (0.06, 0.22)</td>
<td>0.22 (0.11, 0.44)</td>
</tr>
<tr>
<td>ASV584</td>
<td>0.04 (0.02, 0.09)</td>
<td>0.08 (0.04, 0.14)</td>
<td>0.24 (0.13, 0.46)</td>
</tr>
<tr>
<td>ASV355</td>
<td>0.03 (0.01, 0.07)</td>
<td>0.05 (0.03, 0.10)</td>
<td>0.10 (0.06, 0.18)</td>
</tr>
<tr>
<td>ASV87</td>
<td>0.02 (0.01, 0.04)</td>
<td>0.03 (0.02, 0.06)</td>
<td>0.06 (0.03, 0.12)</td>
</tr>
<tr>
<td>ASV1112</td>
<td>0.01 (0.00, 0.03)</td>
<td>0.02 (0.01, 0.04)</td>
<td>0.04 (0.02, 0.08)</td>
</tr>
<tr>
<td>ASV548</td>
<td>0.01 (0.00, 0.03)</td>
<td>0.02 (0.01, 0.04)</td>
<td>0.04 (0.02, 0.08)</td>
</tr>
</tbody>
</table>

(continued...)

WJG | https://www.wjgnet.com | 2324 | June 7, 2022 | Volume 28 | Issue 21 |
ASV436 (Faecalibacterium), ASV763 (Lachnospiraceae_unclassified), and ASV266 (Lachnospiraceae_unclassified) were progressively decreased, and the abundance of ASV779 (Actinomyces) increased from group HC to group T2DM and to group T2DM + OSA (Figure 5B).

**IH-related gut microbiota dysbiosis was associated with abnormal metabolic and inflammatory indicators of T2DM + OSA patients**

We further studied the correlations among metabolic indicators, inflammatory factors, and the above six key ASVs with ascending or decreasing trends. Spearman correlation analysis revealed that the decreased abundance of ASVs showed a significant negative correlation with indicators related to IH or respiratory disorders, such as the ODI and AHI; glucose metabolism indicators, such as HbA1c, FPG, and HOMA-IR; cardiovascular disease-related metabolic indicators, such as HCY; and inflammatory factors, such as CRP, TNF-α, and LBP. The ASV436 (Faecalibacterium) was negatively correlated with the AHI, ODI, FPG, HbA1c, CRP concentrations, and HOMA-IR, while the ASV763 (Lachnospiraceae_unclassified) was negatively correlated with the AHI and FPG, HbA1c, CRP, and LBP concentrations (P < 0.05). Furthermore, the ASV436 (Faecalibacterium), ASV1000 (Eubacterium_eligens_group), and ASV367 (Faecalibacterium) were positively correlated with the mean SpO₂, another IH-related indicator. Among the three groups, the gradually increasing abundance of ASV779 (Actinomyces) showed an opposite relationship; it was significantly positively correlated with the AHI, ODI, and TNF-α concentration and negatively correlated with the mean SpO₂ (P < 0.05) (Figure 6 and Supplementary Table 3).

**DISCUSSION**

T2DM has been linked to gut dysbiosis and chronic inflammation in several clinical and animal experiments[15-17], which may be a consequence of the loss or deficiency in a beneficial function, such as short-chain fatty acid (SCFA)-producing bacteria production from carbohydrate fermentation, in the gut ecosystem[16]. Diseases previously partially attributed to lifestyle, such as obesity and OSAHS, are now considered microbiota-related as well[12,18]. Although much epidemiological and clinical evidence has suggested that OSAHS is an independent risk factor for the development of T2DM[19], the underlying pathogenesis of altered glucose metabolism in T2DM patients with OSAHS remains to be elucidated. Meanwhile, a longitudinal cohort study over a period of 6 years found that the insulin resistance index (HOMA-IR) was a predictor of incident “witnessed apnea”, independent of obesity [20]. This showed that dysglycemia and insulin resistance may lead to the development of OSAHS. Together with the findings of the above-mentioned studies, this strongly suggests that the relationship
Figure 2 The concentrations of inflammatory factors in groups healthy control, type 2 diabetes mellitus, and type 2 diabetes mellitus plus obstructive sleep apnea. A: CRP; B: IL-6; C: IL-17; D: TNF-α; E: TGF-β; F: LBP. Bar charts show the means ± SE of the mean. *P < 0.05 vs healthy control (HC); †P < 0.05 vs type 2 diabetes mellitus. The P value was based on Kruskal–Wallis test or one-way ANOVA. A significant difference was shown by the least significant difference t-test or Mann–Whitney U test. Significant differences were adjusted by Bonferroni correction. CRP: C-reaction protein; IL-6: Interleukin-6; IL-17: Interleukin-17; TNF-α: Tumor necrosis factor-α; TGF-β: Transforming growth factor beta 1; LBP: Lipopolysaccharide-binding protein; HC: Healthy control; T2DM: Type 2 diabetes mellitus; OSA: Obstructive sleep apnea.

between T2DM and OSAHS may be bidirectional[2]. Therefore, it is necessary to investigate whether the imbalance of the intestinal microbiota plays a key role in the pathophysiology underlying metabolic dysfunction of patients with T2DM complicated by OSAHS.

In our study, the sequencing analysis of the 16S rRNA gene-tags applied to fecal samples from T2DM patients complicated by OSAHS showed differences in the relative abundances of the predominant taxa of the genera levels. We found that the concentrations of various IH-related gut bacteria, including SCFA-producing bacteria such as Faecalibacterium and Lachnospiraceae, were significantly correlated with the concentrations of FPG, HbA1c and HOMA-IR, as well as the concentration of HCY, a risk predictor of hypertension and arteriosclerosis[21,22]. IH can result in hypoxia/re-oxygenation cycling events within the gut microbiome and, as a result, the biological diversity of gut microorganisms may be
Figure 3 The gut microbial diversity and structures of the gut microbiota in groups healthy control, type 2 diabetes mellitus, and type 2 diabetes mellitus plus obstructive sleep apnea. A: Shannon index; B: ACE estimator; C: Simpson index; D: Principal coordinates analysis plot of the gut microbiota among groups healthy control, type 2 diabetes mellitus, and type 2 diabetes mellitus plus obstructive sleep apnea. HC: Healthy control; T2DM: Type 2 diabetes mellitus; OSA: Obstructive sleep apnea.

Although the intestinal epithelium is significantly resistant to hypoxia, regulating the absorption and barrier function of the intestinal epithelium is sensitive to the oxygen level in the intestine [23]. Hypoxia/re-oxygenation can directly impair cellular function via an increase in permeability and bacterial translocation and a decrease in tight junction integrity [16]. In addition, studies have shown that after prolonged normoxic recovery after IH exposure, the gut microbiota and circulating endotoxemia remain negatively affected [8]. Our results do not show significant differences in α-diversity and β-diversity. However, the gradual decrease in the relative abundance of SCFA-producing bacteria (such as the ASVs of Faecalibacterium, Eubacterium, and Lachnospiraceae) associated with abnormal indicators of oxygen metabolism, as well as elevated levels of inflammatory indicators (including CRP, IL-17, and TNF-α), which are critically involved in the development of insulin resistance and pathogenesis of T2DM, was observed in T2DM + OSA patients [24]. Emerging evidence shows that SCFAs can modulate glycemic control, exhibit anti-inflammatory and antitumorigenic activity, and decrease oxidative stress [25-28]. Short chain fatty acids contribute to mucin synthesis, decrease bacterial translocation, maintain gut integrity, and mitigate inflammation in the intestine [29, 30]. Thus, we speculated that SCFAs may be regarded as potential targets for recognizing metabolic comorbidities in patients with T2DM complicated by OSAHS.

There are several potential mechanisms by which IH mediates its effect on metabolic dysfunction. It induces macrophages to polarize toward the pro-inflammatory subtype of M1, leading to the production of more pro-inflammatory mediators in visceral adipose tissue, such as TNF-α, IL-6, and IL-8, resulting in subsequent impairment of insulin signaling pathways and insulin resistance [7]. Here, we found that the concentration of Lachnospiraceae was negatively correlated with that of LBP, which is one of the reference indicators of intestinal barrier disruption, suggesting that the induction of inflammatory
processes may be due to the leakage of microbial metabolites into the circulation induced by IH. We found certain changes in the gut microbiota among the three groups over time; however, there were no significant differences between patients with T2DM with and without OSAHS. Nonetheless, the concentrations of inflammatory indicators, such as CRP, TNF-α, and IL-17, were significantly increased in T2DM patients with OSAHS, which indicates that the changes in gut microbiota may have been delayed relative to the chronic inflammatory changes in T2DM patients with OSAHS. On the other hand, some patients with relatively mild disease were included to prevent confounding by factors, including hyperglycemia and obesity, which affect the composition of intestinal microbiota[31]; as a result, the intestinal flora appeared not to have changed remarkably.

Various respiratory diseases have been associated with dysbiosis not only in the airway microbiota but also in the intestinal microbiota[32,33]. This evidence reinforced the existence of a gut-lung axis and the close relationship between intestinal and respiratory compartments; changes at one of the two sites could impact the other[34]. As a minor constituent of the airway microbiota, Actinomyces is related to anaerobic enzymes through GLUT1-dependent glucose elevation and MCT4-dependent lactate transport[35,36]. In our study, we observed that the increase in the relative abundance of Actinomyces
Figure 5 Amplicon sequence variants contributing to the changes in the gut microbiota in groups healthy control, type 2 diabetes mellitus, and type 2 diabetes mellitus plus obstructive sleep apnea. A: The heatmap shows the relative abundance of the 46 amplicon sequence variants (ASVs) significantly different in the three groups. The fold ratio (log2-transformed) indicated the relative abundance of the 46 ASVs between the two different groups \[ P_1: \text{T2DM + OSA vs T2DM}; P_2: \text{T2DM + OSA vs healthy control (HC)}; P_3: \text{HC vs T2DM} \]. \(^a\) \(P < 0.05\), \(^b\) \(P < 0.01\), \(^c\) \(P < 0.001\). Significant difference shown by the Mann–Whitney U test; B: With the increase in disease components, six key ASVs showed increasing or decreasing trends. \(^a\) \(P < 0.05\), \(^b\) \(P < 0.01\).

was positively correlated with OSAHS severity indices and the concentration of TNF-α. We did not test for lung microbes; however, we speculate that they may be related to the gut-lung axis. Further experimental approaches to exploring causal links may be needed.

There are some limitations to our study. First, the sample size was relatively small. Second, the causal relationship between T2DM complicated by OSAHS and the gut microbiota was unclear. Large-scale clinical trials and gnotobiotic mice model validation may be required in the future.
CONCLUSION

T2DM patients with OSAHS may have a higher prevalence of gut microbial dysbiosis. IH may be involved in selective alterations of gut microbiota, which may be related to increased gut permeability and concurrent systemic inflammatory changes in patients with T2DM complicated by OSAHS. These findings provide foundations for further studies on the mechanisms and interventional approaches aimed at restoration of the gut microbiota to prevent or to palliate the adverse effects of T2DM patients with OSAHS.

ARTICLE HIGHLIGHTS

Research background
Obstructive sleep apnea (OSA)-hypopnea syndrome (OSAHS), as a chronic and treatable sleep disorder, has a high prevalence in type 2 diabetes mellitus (T2DM) patients. As a landmark feature of OSAHS, intermittent hypoxia (IH) plays an important role in the occurrence and development of related complications in T2DM patients. However, the pathological mechanisms are varied and unknown. Therefore, it is important to study the role of gut microbiota, a meaningful new target, in T2DM patients with OSAHS.

Research motivation
In recent years, it has been found that gut microbiota imbalance is related to metabolic diseases. However, most studies have not discussed the relationship between gut microbiota changes and T2DM patients with OSAHS.

Research objectives
In this study we focused on IH that might be involved in altering the gut dysbiosis in T2DM patients with OSAHS. Meanwhile, we further assessed the changes of clinical indicators and inflammatory factors related to dysbiosis, aiming to provide new targets and perspectives for the pathogenesis and prevention strategies of T2DM patients complicated with OSAHS.

Research methods
A case-control study was conducted to select subjects who were divided into T2DM + OSA group, T2DM group, and healthy control group. They were examined with a type IV portable monitor.
overnight. The clinical indexes, respiratory parameters, inflammatory indexes, and gut microbial community of the three groups were measured.

**Research results**
Among the three groups, T2DM + OSA group showed the most severe changes in sleep apnea parameters and increased systemic inflammatory factors. We found the decreased levels of short-chain fatty acid-related *Faecalibacterium*, *Eubacterium*, and *Lachnospiraceae* and the increased levels of *Actinomyces* at the amplicon sequence variant level. The changes in these gut microorganisms were closely related to clinical indicators as well.

**Research conclusions**
IH may be involved in the selective changes of intestinal microbiota, which may be related to the increased intestinal permeability and systemic inflammation response in T2DM patients with OSAHS.

**Research perspectives**
This study shows that IH may change the state of gut microbiota and systemic inflammation, which participate in the occurrence and development of T2MD complicated with OSAHS. In the future, large-scale clinical randomized controlled prospective trials and animal trials may be needed to further explore the corresponding causality.

**ACKNOWLEDGEMENTS**
We would like to thank the participants involved in this study.

**FOOTNOTES**

**Author contributions:** Tang SS designed the research and conducted microbiome analysis; Liu YL conducted the research except the microbiome analysis; Tang SS and Liang CH analyzed the microbiome data and wrote the paper; all other data were analyzed by Shi XY and Deng XR with oversight by Wei W; Zhang LJ and Wang LM were responsible for the data acquisition and input and proofreading of the manuscript; Tang SS and Yuan HJ had primary responsibility for the final content; all authors have read and approved the final manuscript.

**Supported by:** National Natural Science Foundation of China, No. 81970705; and Central Plains Thousand Talents Plan, No. 204200510026.

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of Henan Provincial People’s Hospital (IRB No. 2019-62).

**Informed consent statement:** All study participants provided informed written consent before the study enrollment.

**Conflict-of-interest statement:** All authors declare no conflicts of interest.

**Data sharing statement:** Raw sequencing data and associated metadata were deposited in the NCBI short-read archive with BioProject accession number PRJNA788301.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: [https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)

**Country/Territory of origin:** China

**ORCID number:** Sha-Sha Tang 0000-0002-1307-3123; Cheng-Hong Liang 0000-0003-0661-9472; Yu-Lei Liu 0000-0003-0946-4605; Wei Wei 0000-0003-1045-1449; Xin-Ru Deng 0000-0003-3747-9310; Xiao-Yang Shi 0000-0001-7917-2048; Li-Min Wang 0000-0002-6396-390X; Li-Jun Zhang 0000-0003-1401-5775; Hui-Juan Yuan 0000-0002-0486-0994.

**S-Editor:** Fan JR
**L-Editor:** A
**P-Editor:** Yu HG
REFERENCES


25 Kasahara K, Krautkramer KA, Org E, Romano KA, Kerby RL, Vivas EI, Mehrabian M, Denu JM, Bäckhed F, Lusis AJ, 

26 Xu J, Liang R, Zhang W, Tian K, Li J, Chen X, Yu T, Chen Q. Faecalibacterium prausnitzii-derived microbial anti-

27 Kang JD, Myers CJ, Harris SC, Kakiyama G, Lee IK, Yun BS, Matsuzaki K, Furukawa M, Min HK, Bajaj JS, Zhou H, 
Hylemon PB. Bile Acid 7α-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit Clostridium difficile: Role of 


30 Moustafa A, Li W, Anderson EL, Wong EHM, Dulai PS, Sandborn WJ, Biggs W, Yooseph S, Jones MB, Venter JC, 

31 He FF, Li YM. Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic 

32 Bruzzone E, Callegari ML, Raia V, Viscoxo S, Scotto R, Ferrari S, Morelli L, Bucciogrossi V, Lo Vecchio A, Roberto E, 
Guarino A. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration 


35 Huang D, Su X, Yuan M, Zhang S, He J, Deng Q, Qiu W, Dong H, Cai S. The characterization of lung microbiome in lung 
